Request Your Free White Paper Now:

"From Data to Decision: Biomarkers Shaping the Future of Gastric Cancer Treatment"

Download this free whitepaper to learn more.

NeoGenomics’ latest white paper explores how actionable and emerging biomarkers are transforming therapeutic strategies in gastric and gastroesophageal junction cancers. With a focus on real-world data and clinical trial insights, the paper highlights how biomarker-driven decisions are enabling more personalized and effective care.

Key Highlights:

• CLDN18.2 is a leading biomarker driving new targeted therapies, including zolbetuximab and CAR-T innovations.
• NeoGenomics data supports biomarker-guided treatment, with high prevalence of PD-L1 and CLDN18.2.
• Clinical trials confirm improved outcomes with biomarker-driven approaches.
• Precision oncology is advancing with novel therapies like ADCs, bispecifics, and CAR-T.

This white paper is a must-read for oncology professionals seeking to stay ahead of the curve in precision medicine and biomarker-guided treatment.

Offered Free by: NeoGenomics
See All Resources from: NeoGenomics